Craig Hallum Begins Coverage on LifeVantage (NASDAQ:LFVN)

Craig Hallum initiated coverage on shares of LifeVantage (NASDAQ:LFVN) in a report released on Tuesday morning, MarketBeat reports. The firm issued a buy rating and a $35.00 target price on the stock.

Separately, Lake Street Capital started coverage on LifeVantage in a research note on Thursday, December 19th. They issued a “buy” rating and a $26.00 price objective for the company.

LifeVantage Trading Up 11.4 %

NASDAQ:LFVN opened at $25.62 on Tuesday. LifeVantage has a twelve month low of $5.22 and a twelve month high of $27.38. The company has a market cap of $320.89 million, a PE ratio of 80.07 and a beta of 0.82. The company’s 50 day moving average is $16.07 and its two-hundred day moving average is $11.77.

LifeVantage (NASDAQ:LFVN) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $0.15 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.15. The firm had revenue of $47.21 million for the quarter. LifeVantage had a net margin of 2.11% and a return on equity of 29.24%.

LifeVantage Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, December 16th. Investors of record on Monday, December 2nd were issued a dividend of $0.04 per share. The ex-dividend date was Monday, December 2nd. This represents a $0.16 annualized dividend and a dividend yield of 0.62%. LifeVantage’s dividend payout ratio (DPR) is presently 50.00%.

Institutional Investors Weigh In On LifeVantage

Hedge funds have recently added to or reduced their stakes in the business. Ritholtz Wealth Management raised its stake in shares of LifeVantage by 62.0% during the 3rd quarter. Ritholtz Wealth Management now owns 28,666 shares of the company’s stock valued at $346,000 after buying an additional 10,974 shares during the last quarter. Barclays PLC grew its holdings in LifeVantage by 38.2% during the third quarter. Barclays PLC now owns 41,966 shares of the company’s stock worth $507,000 after acquiring an additional 11,608 shares during the period. HighTower Advisors LLC purchased a new position in LifeVantage during the third quarter valued at approximately $638,000. Capital Management Corp VA purchased a new position in shares of LifeVantage during the 3rd quarter valued at approximately $5,073,000. Finally, Renaissance Technologies LLC lifted its stake in shares of LifeVantage by 2.1% in the 2nd quarter. Renaissance Technologies LLC now owns 855,118 shares of the company’s stock valued at $5,490,000 after purchasing an additional 17,300 shares during the period. 35.32% of the stock is owned by hedge funds and other institutional investors.

LifeVantage Company Profile

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.